Want to see IRD full AI Analyst Report?
IRD Stock Chart & Stats
$3.08
$0.16(5.48%)
At close: 4:00 PM EDT
$3.08
$0.16(5.48%)
Day’s Range― - ―
52-Week Range$1.10 - $5.81
Previous CloseN/A
Volume1.09M
Average Volume (3M)1.08M
Market Cap
$300.34M
Enterprise Value$405.18
Total Cash (Recent Filing)$88.81M
Total Debt (Recent Filing)$34.93M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 17, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding83,195,820
10 Day Avg. Volume943,049
30 Day Avg. Volume1,081,647
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$13.47M
Bulls Say, Bears Say
Bulls Say
Diversified Clinical PipelineA portfolio of five advancing gene‑therapy programs spreads development risk across multiple IRD indications, increases chances of successful readouts across 2027, and leverages rare-disease incentives and partnerships to create multiple durable value inflection points beyond any single trial outcome.
Registrational Phase 3 Enrollment CompleteCompleting enrollment in a pivotal registrational trial materially reduces execution and recruitment risk for that program, clarifies the regulatory pathway, and positions the company for near-term clinical readouts and potential filing milestones that can meaningfully de‑risk long‑term commercial prospects if results are positive.
Financing Optionality Via Shelf FilingA $300M mixed securities shelf provides structural financing optionality, allowing the company to access public capital markets on flexible terms to fund multiyear clinical programs; this reduces immediate solvency pressure and supports executing the development plan without relying solely on short‑term private financings.
Bears Say
Material Balance Sheet DeteriorationNegative equity combined with newly incurred debt represents a structural weakening of financial flexibility, raising refinancing and covenant risks. Over months, this constrains strategic options, increases cost of capital, and heightens the likelihood of dilutive financing if clinical progress stalls or expenses exceed forecasts.
Sustained High Cash BurnPersistent negative operating and free cash flow at this scale requires ongoing external funding to support R&D and trials. Structural reliance on capital markets increases financing risk, could force dilutive raises or program cuts, and makes long‑term execution contingent on continued investor access and successful milestones.
Revenue Decline With Unstable ProfitabilityDeclining revenue and extreme negative margins show the company remains pre‑commercial with earnings volatile. Although gross margins appear high conceptually, they are theoretical until products are commercialized; current low sales and high fixed R&D costs create a structurally loss‑making profile until successful approvals or partnerships materialize.
Opus Genetics News
IRD FAQ
What was Opus Genetics, Inc.’s price range in the past 12 months?
Opus Genetics, Inc. lowest stock price was $1.10 and its highest was $5.81 in the past 12 months.
What is Opus Genetics, Inc.’s market cap?
Opus Genetics, Inc.’s market cap is $300.34M.
When is Opus Genetics, Inc.’s upcoming earnings report date?
Opus Genetics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 91 days.
How were Opus Genetics, Inc.’s earnings last quarter?
Opus Genetics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.017.
Is Opus Genetics, Inc. overvalued?
According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued.
Does Opus Genetics, Inc. pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
What is Opus Genetics, Inc.’s EPS estimate?
Opus Genetics, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Opus Genetics, Inc. have?
Opus Genetics, Inc. has 83,195,820 shares outstanding.
What happened to Opus Genetics, Inc.’s price movement after its last earnings report?
Opus Genetics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went down -1.587%.
Which hedge fund is a major shareholder of Opus Genetics, Inc.?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (257.14% Upside)
$11.00 (257.14% Upside)
Blogger Sentiment
Neutral
IRD Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 135.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.44%
Trailing 12-Months
Company Description
Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$11.00
▲(257.14% Upside)
Technical Analysis
Ownership Overview
13.84% Insiders
3.48% Mutual Funds
40.53% Other Institutional Investors
35.47% Public Companies and
Individual Investors